Skip to content

Judicial Watch • HPVgrants

HPVgrants

HPVgrants

Page 1: HPVgrants

Category:

Number of Pages:30

Date Created:August 8, 2013

Date Uploaded to the Library:October 24, 2013

Tags:HHS, EPA, IRS, ICE, CIA


File Scanned for Malware

Donate now to keep these documents public!

  • demand_answers

See Generated Text   ˅

Autogenerated text from PDF

Table Contents
Part Overview Information
Part Full Text the Announcement
Section
Funding Opportunity Description
Section II.
Award Information
Section III.
Eligibility Information
Section IV. Application and Submission Information
Section
Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
PART OVERVIEW INFORMATION
DEPARTMENT HEALTH AND HUMAN SERVICES
Federal Agency Name: Centers for Disease Control and Prevention (CDC)
Funding Opportunity Title: PPHF 2013: Immunization Increasing Human
Papillomavirus (HPV) Vaccination Coverage Rates among Adolescents financed solely 2013 Prevention and Public Health Funds
Announcement Type:
 Revision Type
Agency Funding Opportunity Number: CDC-RFA-IP13-130101PPHF13
Catalog Federal Domestic Assistance Number: 93.539
Key Dates:
Letter Intent Deadline: August 16, 2013, 5:00 p.m. Eastern Time
Application Deadline Date: September 2013, 5:00 p.m. Eastern Time
Executive Summary:
Results the 2011 NIS Teen survey, conducted roughly years after the 2006 licensure the quadrivalent human papillomavirus (HPV4) for use females, demonstrate that
nearly half females aged years sampled 2011 had not yet received their
recommended first HPV vaccine dose, and over 65% had not received doses
CDC Supplement Non-Research
Rev. 01/2011
recommended the Advisory Committee Immunization Practices (ACIP). only
30.0%, coverage among females aged years lagged behind the Healthy People
2020 goal 80% coverage for human papillomavirus (HPV) vaccine doses.
contrast, coverage estimates among all teens aged years for dose tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis (Tdap) and dose quadrivalent
meningococcal conjugate (MenACWY) were 80.5% and 71.5%, respectively,
highlighting that 80% coverage achievable among adolescents. These findings also
indicate that opportunities for co-administration HPV vaccine with other
recommended vaccines are being missed. further concern that vaccination coverage
for HPV dose appears plateauing among the adolescent female population;
coverage only increased percentage points from 2010 2011, roughly half the
percentage point increases observed for Tdap and MenACWY, respectively.
Through independent work well collaborative initiatives led selected
immunization program awardees, this FOA designed use evidence-based practices
and tools address issues that have been identified barriers increasing HPV
vaccination coverage. These issues include providers failing render strong HPV
vaccination recommendations every opportunity (in the absence clinical
contraindication), shifting limited HPV vaccination administration practices older
teens (i.e., rather than vaccinating year olds, consistent with ACIP
recommendations), and lacking knowledge regarding HPV vaccination indications and
HPV disease. Other barriers appear stem from parental perceptions and educational
needs. helping address the fact that parents are not knowledgeable about HPV
vaccination recommendations, this FOA also intended increase demand for, and
acceptance of, HPV vaccination.
Purpose
The purpose the program increase HPV vaccination coverage among adolescents
by: Developing jurisdiction-wide joint initiative with immunization stakeholders, Implementing comprehensive communication campaign targeted the public, Implementing Immunization Information System (IIS)-based reminder recall for
adolescents aged years either through centralized approach (preferred) providing support immunization providers, Using assessment and feedback evaluate and improve the performance
immunization providers administering the 3-dose HPV vaccine series
consistent with current ACIP recommendations, and Implementing strategies targeted immunization providers Increase knowledge regarding HPV-related diseases (including cancers), Increase knowledge regarding HPV vaccination safety and effectiveness, Improve skills needed deliver strong, effective HPV vaccination
recommendations,
CDC Supplement Non-Research
Rev. 01/2011 Decrease missed opportunities for timely HPV vaccination and series
completion, and Increase administration HPV vaccine doses consistent with current ACIP
recommendations.
Measurable outcomes the FOA will alignment with one (or more) the
following performance goal(s) for the National Center for Immunization and Respiratory
Diseases: Ensure that children and adolescents are appropriately vaccinated; well
CDC health protection goal: Healthy People Every Stage Life. This overall FOA
addresses the following Healthy People 2020 objectives:
IID 11.4 Increase the vaccination coverage level doses human papillomavirus
vaccine for females age years
This announcement only for non-research activities supported CDC. research
proposed, the application will not reviewed. For the definition research, please see
the CDC Web site the following Internet address:
http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-healthresearch-nonresearch.pdf.
PART FULL TEXT FUNDING OPPORTUNITY DESCRIPTION
Statutory Authority
This project authorized under section 301 and 317 the Public Health Service Act
(PHS Act), USC, 241 and 247b amended and the Patient Protection and Affordable
Care Act (PL 111-148).
Background
Overview HPV Epidemiology, Clinical Outcomes, and Vaccination Recommendations the United States, estimated million persons are newly infected annually with
genital human papillomavirus (HPV), making this infection the nation most common
sexually transmitted infection. Nearly half new HPV infections occur among persons
aged years. Although most infections are asymptomatic and resolve, persistent
infections can cause disease, including cancers. Currently, cure exists for HPV
infection; treatments can only directed HPV-associated lesions.
Almost all cervical cancers and many vaginal, vulvar, anal, penile, and oropharyngeal
cancers are attributable persistent, oncogenic HPV infections. 2009, nearly 35,000
CDC Supplement Non-Research
Rev. 01/2011
HPV-attributable cancers were reported the United States. these, 39% occurred
males.
Approximately 100 HPV types have been described; HPV types and cause 70%
cervical cancers. Among types associated with other HPV-related cancers, HPV
most prevalent. Non-oncogenic types can result clinically significant disease; HPV
types and can cause recurrent respiratory papillomatosis rare condition which
warts develop the respiratory tract) and cause nearly all genital warts.
Two HPV vaccines are currently licensed the United States for prevention specific
HPV types and HPV-associated outcomes. June 2006, quadrivalent HPV vaccine
(HPV4; Gardasil; Merck Co., Inc.) was licensed the Food and Drug Administration
(FDA) for use females for prevention cervical cancer, cervical cancer precursors,
vulvar and vaginal cancer precursors, and anogenital warts caused HPV types 11, and 18. 2008, HPV4 indications were expanded include vulvar and vaginal
cancers. 2009, HPV4 was licensed for use males for genital warts prevention. Also 2009, the FDA licensed bivalent HPV vaccine (HPV2; Cervarix; GlaxoSmithKline) for
use females for prevention cervical cancer and cervical cancer precursors caused
HPV types and 18. December 2010, HPV4 indications were expanded include
anal cancer prevention females and males. Both vaccines are administered 3-dose
series over months.
The Advisory Committee Immunization Practices (ACIP) currently recommends
routine HPV vaccination for all persons aged years. For females, ACIP
recommends either HPV4 HPV2; for males, ACIP recommends HPV4 (HPV2 not
licensed for males). For persons who have not initiated completed the series,
vaccination recommended for females through age years and for males through age years. For unvaccinated incompletely vaccinated immunocompromised males
men who have sex with men, vaccination recommended through age years.
Review HPV Vaccination Coverage Data
Results the 2011 NIS Teen survey, conducted roughly years after the 2006 licensure the quadrivalent human papillomavirus (HPV4) for use females, demonstrate that
nearly half females aged years sampled 2011 had not yet received their
recommended first HPV vaccine dose, and over 65% had not received doses
recommended the Advisory Committee Immunization Practices (ACIP). only
30.0%, coverage among females aged years lagged behind the Healthy People
2020 goal 80% coverage for human papillomavirus (HPV) vaccine doses.
contrast, coverage estimates among all teens aged years for dose tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis (Tdap) and dose quadrivalent
meningococcal conjugate (MenACWY) were 80.5% and 71.5%, respectively,
highlighting that 80% coverage achievable among adolescents. These findings also
indicate that opportunities for co-administration HPV vaccine with other
CDC Supplement Non-Research
Rev. 01/2011
recommended vaccines are being missed. further concern that vaccination coverage
for HPV dose appears plateauing among the adolescent female population;
coverage only increased percentage points from 2010 2011, roughly half the
percentage point increases observed for Tdap and MenACWY, respectively.
Among girls aged years, coverage with HPV vaccine dose ranged from 39.1%
(Mississippi) 76.1% (Rhode Island), while coverage with HPV vaccine doses
varied from 15.5% (Arkansas) 56.8% (Rhode Island). For both and HPV
vaccine doses, southern states had significantly lower coverage than states the
northeast and west. Mississippi and Arkansas are among the states with the highest
incidences HPV-associated cervical cancers.
Overall, among males aged years, 8.3% (CI 7.3 9.3) had received dose and
1.3% (CI=1.0 1.6) had received doses HPV vaccine. Completion the HPV
series among those who initiated the series and had least six months between the first
dose and the NIS-Teen interview date was documented only among 70.7% (CI= 68.4 
73.0) females and 28.1% (CI= 21.6 34.6) males. Notably, coverage estimates
among males 2011 reflect vaccination practices related the 2009 guidance from the
ACIP that HPV4 could administered males aged years and not reflect
uptake after the routine recommendation for vaccination males, which was made
October 2011.
Addressing Barriers Increasing HPV Vaccination Coverage
According the 2011 NIS Teen survey, the top reasons cited parents both girls
and boys who expressed intention vaccinate their teens the ensuing months
following interviews included not recommended, not needed necessary, lack
knowledge, and [child] not sexually active. Parents females also cited safety
concerns and side effects. The NIS-Teen finding regarding lack knowledge and
parents perception that the vaccine not needed consistent with other research. For
example, national consumer health surveys conducted 2007 substantiated that, among
surveyed parents adolescents 1,208), only 21% were able identify the vaccines,
including HPV vaccine, that were recommended for adolescents the time the survey.
While the reports parents males regarding the vaccine not being recommended
likely stem from the timing the survey administration relative the 2011 ACIP
recommendation for males, the fact that parents girls cited lack recommendation
concerning.
Studies consistently indicate that healthcare provider recommendation the single
strongest predictor vaccination status. Formative research with healthcare providers,
including pediatricians, family practitioners, and nurses, clearly and consistently indicate
that increased education needed regarding vaccines recommended for adolescents, with
emphasis evolving HPV vaccination recommendations, which now include males.
CDC Supplement Non-Research
Rev. 01/2011
addition, interviewed providers have requested educational materials for both themselves
(to facilitate improved communication with parents) well for parents (to increase
parental awareness and education). Staff members from the Centers for Disease Control
and Prevention (CDC) have developed in-depth materials for both providers and parents
with pre-tested messages stemming from formative research. Dissemination these
materials parents and providers needed foster increased HPV vaccination
coverage.
Evidenced based strategies that are recommended the Task Force Community
Preventive Services for increasing vaccination coverage include reminder/recall and
assessment and feedback. Reminder/recall involves informing members target
population that one more vaccinations are due (reminders) late (recall); assessment
and feedback entails retrospectively assessing providers performances delivering one more vaccinations client population and giving this information (feedback)
providers. While several studies have shown reminder/recall effective, few
providers have incorporated reminder/recall into their practices. Assessment and
feedback has also been shown effective improving infant vaccination coverage
levels, but few immunization programs have expanded assessment and feedback
activities the adolescent population.
Both reminder/recall and assessment activities can resource intensive the absence
well-organized electronic data. Immunization information systems (IIS) (i.e.,
confidential, computerized information systems that collect and consolidate vaccination
data from multiple health-care providers) make possible for immunization programs
and providers generate reminder/recall notifications and assess vaccination coverage
levels standardized and timely manner. recently published study indicates that,
compared with practice-based recall, centralized recall was more cost-effective and
effective improving immunization rates among preschool children.
Under current operational funding, immunization program awardees are limited their
abilities use IIS engage reminder/recall activities for adolescents, and they are
able provide AFIX visits only ~25% all Vaccines for Children (VFC) program
providers annually. This FOA intended facilitate use IIS for reminder/recall
adolescents due overdue for HPV vaccination and other vaccines, expansion AFIX
visits more providers caring for adolescents, and emphasis during AFIX visits
promotion timely HPV vaccination consistent with current ACIP recommendations. addition the VFC program and the Section 317 immunization grant program, CDC
administers two federal programs with the potential decrease HPV-associated cancer
incidence, morbidity, and mortality. Through cooperative agreements with awardees
nationwide, CDC Division Cancer Prevention and Control provides funding for the
National Comprehensive Cancer Control Program (NCCCP) and the National Breast and
Cervical Cancer Early Detection Program (NBCCEDP). The NBCCEDP program, the
CDC Supplement Non-Research
Rev. 01/2011
VFC program, and the Section 317 immunization grant program are designed remove
cost barrier health care and serve populations with greatest need well
increased risks infection and disease. Through the NCCCP, CDC currently supports
the development and implementation cancer control plans states, the District
Columbia, tribal groups, and U.S. Associated Pacific Islands/territories. Applicants
responding this FOA are encouraged consider and create opportunities within their
jurisdictions leverage the strengths these four federal programs.
Through independent work well collaborative initiatives led selected
immunization program awardees, this FOA designed use evidence-based practices
and tools address issues that have been identified barriers increasing HPV
vaccination coverage. These issues include providers failing render strong HPV
vaccination recommendations every opportunity (in the absence clinical
contraindication), shifting limited HPV vaccination administration practices older
teens (i.e., rather than vaccinating year olds, consistent with ACIP
recommendations), and lacking knowledge regarding HPV vaccination indications and
HPV disease. Other barriers appear stem from parental perceptions and educational
needs. helping address the fact that parents are not knowledgeable about HPV
vaccination recommendations, this FOA also intended increase demand for, and
acceptance of, HPV vaccination.
Purpose
The purpose the program increase HPV vaccination coverage among adolescents
by: Developing jurisdiction-wide joint initiative with immunization stakeholders, Implementing comprehensive communication campaign targeted the public, Implementing Immunization Information System (IIS)-based reminder recall for
adolescents aged years either through centralized approach (preferred) providing support immunization providers, Using assessment and feedback evaluate and improve the performance
immunization providers administering the 3-dose HPV vaccine series
consistent with current ACIP recommendations, and Implementing strategies targeted immunization providers Increase knowledge regarding HPV-related diseases (including cancers), Increase knowledge regarding HPV vaccination safety and effectiveness, Improve skills needed deliver strong, effective HPV vaccination
recommendations, Decrease missed opportunities for timely HPV vaccination and series
completion, and Increase administration HPV vaccine doses consistent with current ACIP
recommendations.
CDC Supplement Non-Research
Rev. 01/2011
This program addresses the Healthy People 2020 focus area(s)
IID 11.4 Increase the vaccination coverage level doses human papillomavirus
vaccine for females age years.
Program Implementation
Recipient Activities Develop jurisdiction-wide joint initiative with stakeholders including public
health immunization well cancer prevention and control programs, other
government entities (including Medicaid programs, the Indian Health Service),
community health centers, federally qualified health centers (FQHCs), rural health
centers (RHCs), non-governmental organizations including (but not necessarily
limited to) immunization coalitions, cancer prevention and control organizations,
comprehensive cancer control coalitions, clinical partners, managed care
organizations and large health systems, insurers, professional organizations [e.g.,
state/local chapters organizations such the American Academy Pediatrics
(AAP), state/local members organizations such the National Association
Chronic Disease Directors], and others.
Note: anticipated that the additional activities described below will
integral (and might expanded through) the HPV vaccination joint initiative,
but the activities below should started soon possible following award
notification. This should reflected applicants timelines. Implement comprehensive communication campaign targeted the public, with
emphasis reaching parents guardians children aged years.
Awardees are strongly encouraged to: Use CDC materials that include pre-tested messages stemming from
formative research; this will facilitate rapid implementation
communication campaign promote HPV vaccine awareness and
acceptance,
ii) Allocate 25% award funds this communication campaign,
iii) Include public information officers directors communication
planning and implementing proposed communication campaigns.
Awardees may consider including communication campaigns:
(i) Information and messages promote eligible adolescents receipt
recommended vaccines through the Vaccines for Children Program,
(ii) Information and messages, where appropriate, inform the public
impending reminder/recall activities;
CDC Supplement Non-Research
Rev. 01/2011
(iii)Plans translate existing materials into languages accessible the
jurisdiction largest minority groups. Translations and formats that are
culturally sensitive are encouraged. Materials should shared back with
CDC communications staff and other awardees facilitate potential
dissemination beyond single jurisdiction and prevent duplication
efforts. Implement Immunization Information System (IIS)-based reminder/recall for
adolescents aged years either through centralized approach (the
immunization program conducts all activities, but informs providers the
reminder/recall planned) providing support immunization providers (i.e., the
immunization program recruits and trains providers, who then disseminate all
reminder/recall notices). The centralized approach preferred due evidence
showing greater cost-effectiveness and effectiveness this approach compared
provider-based reminder/recall. Use assessment and feedback evaluate the performance providers
administering the 3-dose HPV vaccine series consistent with current ACIP
recommendations and present this information providers guide changes,
needed, their clinical practice patterns. Implement strategies targeted immunization providers to: Increase knowledge regarding HPV-related diseases (including cancers), Increase knowledge regarding HPV vaccination safety and effectiveness, Improve skills needed deliver strong, effective HPV vaccination
recommendations, Decrease missed opportunities for timely HPV vaccination and series
completion, and Increase administration HPV vaccine doses consistent with current ACIP
recommendations.
Applicants are strongly encouraged to:
 Use CDC materials that include pre-tested messages stemming from
formative research.
 Tie education and outreach activities other activities, including reminder
recall and assessment and feedback, whenever feasible.
 Design interventions help practices identify sustainable, long-term
strategies avoid missed vaccination opportunities both well and acute
care visits.
 Target interventions include all staff members practices providing
immunizations adolescents (e.g., physicians, physician extenders, nurses,
medical assistants, reception appointment scheduling staff) and promote
awareness the importance every staff member knowledge, attitudes,
CDC Supplement Non-Research
Rev. 01/2011
 
and beliefs facilitating timely HPV vaccination for adolescents affiliated
with that practice.
Expand and facilitate education and outreach activities much feasible
through the stakeholders participating the jurisdiction-wide HPV
vaccination joint initiative described above. For example, local hospitals
might host speakers for Grand Rounds presentations. Professional
organizations (e.g., state AAP chapters) meetings might host invited speakers annual periodic conferences. Because immunization providers 
attendance participation rates activities offering continuing education (CE)
are likely greater than events without CE, applicants are encouraged pursue accreditation for outreach targeting immunization providers. Applicants should plan to: Participate regular project calls with CDC follows: Bi-weekly during the first 3-6 months the project
ii. Monthly thereafter Submit quarterly progress reports with quantitative measures. Participate limited conference calls with other awardees funded through this
FOA. Attend reverse site visit Atlanta, GA. Disseminate lessons learned through presentations HPV vaccination joint
initiative stakeholders and through presentations other appropriate venues
and partner collaboration. cooperative agreement, CDC staff substantially involved the program
activities, above and beyond routine grant monitoring.
CDC Activities Review and comment award recipients proposed implementation plans and
identify gaps, opportunities, synergies. Monitor awardees progress meeting timelines and milestones. Identify
challenges through conference calls, monthly reports, and budget expenditures. Provide technical assistance, needed, awardees regarding current issues
related HPV disease and vaccination, project implementation, budget, and
evaluation activities. Collaborate with award recipients develop process and outcome measures that
can used awardees demonstrate progress toward improving HPV
vaccination coverage among adolescents. These process and outcome measures
will incorporated each award recipient into reports submitted CDC. Facilitate awardee reverse site visits and, needed, multi-awardee conference
calls provide enhanced technical assistance, address challenges/barriers, and
promote sharing best practices.
CDC Supplement Non-Research
Rev. 01/2011
II. AWARD INFORMATION
Type Award: Cooperative Agreement.
Award Mechanism: H23 Immunization Grants and Vaccines for Children
Fiscal Year Funds: 2013
Approximate Total Supplemental Funding: $7,000,000 (This amount subject
availability funds. This includes direct and indirect costs. The government reserves
the right adjust award amounts for program areas agency and public health priorities
change.
Approximate Number Awards: This will depend the number and quality
applications and the available funding.
Approximate Average Award: $700,000 (This amount for 15-month budget period,
and includes both direct and indirect costs.)
Floor Individual Award Range: $400,000
Ceiling Individual Award Range: $1,000,000 (This ceiling for 15-month budget
period.) This for total cost, which would include indirect costs. Although the ceiling
$1,000,000, CDC will allow higher amount requested $1,400,000 the
awardee proposes significant media campaigns partnership activities.
Anticipated Award Date: September 30, 2013
Budget Period Length: months
Project Period Length: months
III. ELIGIBILITY INFORMATION
Eligible Applicants
The following recipients may submit application:
Applicants must one the Immunization Program awardees currently funded
under CDC-RFA-IP13-1301 Immunization and Vaccines for Children Program
ensure availability the necessary infrastructure perform the activities required and
the experience needed complete the required functions successfully.
Required Registrations
Central Contractor Registration and Universal Identifier Requirements
All applicant organizations must obtain DUN and Bradstreet (DB) Data Universal
Numbering System (DUNS) number the Universal Identifier when applying for
Federal grants cooperative agreements. The DUNS number nine-digit number
assigned Dun and Bradstreet Information Services.
CDC Supplement Non-Research
Rev. 01/2011
The recipient required have the original DUNS identifier apply for additional
funds. AOR should consulted determine the appropriate number. the organization
does not have DUNS number, AOR should complete the DB D-U-N-S
Number Request Form contact Dun and Bradstreet telephone directly 1-866705-5711 (toll-free) obtain one. DUNS number will provided immediately
telephone charge. Note this organizational number. Individual Program
Directors/Principal Investigators not need register for DUNS number.
Additionally, all applicant organizations must register the Central Contractor Registry
(CCR) and maintain their CCR registration with current information all times during
which has application under consideration for funding CDC and, award
made, until final financial report submitted the final payment received,
whichever later. CCR the primary registrant database for the Federal government and the repository into which entity must provide information required for the conduct business recipient. Additional information about registration procedures may
found the CCR internet site www.ccr.gov. award granted, the grantee organization must notify potential sub-recipients that organization may receive sub-award under the grant unless the organization has
provided its DUNS number the grantee organization.
Cost Sharing Matching
Cost sharing matching funds are not required for this program.
Other funding amount greater than the ceiling the award range requested, the
application will considered non-responsive and will not entered into the review
process. The recipient will notified that the application did not meet the eligibility
requirements.
Note: Title the United States Code Section 1611 states that organization described Section 501(c)(4) the Internal Revenue Code that engages lobbying activities
not eligible receive Federal funds constituting grant, loan, award.
Maintenance Effort
Maintenance Effort not required for this program.
CDC Supplement Non-Research
Rev. 01/2011
IV. Application and Submission Information
Address Request Application Package
Applicants must download the SF424 (RR) application package associated with this
funding opportunity from Grants.gov. access the Internet not available the
applicant encounters difficulty accessing the forms on-line, contact the HHS/CDC
Procurement and Grants Office Technical Information Management Section (PGO
TIMS) staff (770) 488-2700 for further instruction. CDC Telecommunications for the
hearing impaired disable available at: TTY 1-888-232-6348. the applicant encounters technical difficulties with Grants.gov, the applicant should
contact Grants.gov Customer Service. The Grants.gov Contact Center available
hours day, days week, with the exception all Federal Holidays. The Contact
Center provides customer service the applicant community. The extended hours will
provide applicants support around the clock, ensuring the best possible customer service received any time needed. You can reach the Grants.gov Support Center 1-800518-4726 email support@grants.gov. Submissions sent email, fax,
thumb drives applications will not accepted.
Content and Form Application Submission
Unless specifically indicated, this announcement requires submission the following
information:
Letter Intent (LOI):
Prospective applicants are requested submit letter intent that includes the
following information:
 Number and title this funding opportunity
 Descriptive title proposed project
 Name, address, and telephone number the Principal Investigator/Project
Director
 Names any key personnel known
 Planned participating institutions known
LOI Submission Address: Submit the LOI express mail, delivery service, fax,
email to:
Ms. Harriette Lynch
CDC, NCHHSTP, Extramural Non-Research Unit
1600 Clifton Road, NE, Mailstop E-07
Atlanta, 30329
Telephone: 404-718-8837
Fax: 404-639-8606
E-mail: HLynch@cdc.gov
CDC Supplement Non-Research
Rev. 01/2011
Although letter intent not required, not binding, and does not enter into the
review application, the information that contains allows CDC program staff
estimate and plan the review submitted applications. Requested LOIs should
provided not later than the date indicated Part Overview Information.
Note: Limit file names characters and not use special characters (e.g. including periods (.), blank spaces and accent marks within application form fields
and file attachment names. underscore (_) may used separate file name. Also, not attach multiple documents with the same file name. All information submitted
must typed. Project Abstract must completed the Grants.gov application forms. The Project
Abstract must contain summary the proposed activity suitable for dissemination
the public. should self-contained description the project and should contain
statement objectives and methods employed. should informative other
persons working the same related fields and insofar possible understandable
technically literate lay reader. This abstract must not include any proprietary/confidential
information. The Project Abstract may single-spaced. Project Narrative must submitted with the application forms. The project narrative
must uploaded PDF file format when submitting via Grants.gov. The narrative
must submitted the following format:
 Maximum number pages: 15; your narrative exceeds the page limit, only the
first pages which are within the page limit will reviewed.
 Font size: point unreduced, Times New Roman
 Double spaced
 Page margin size: One inch
 Number all narrative pages; not exceed the maximum number pages.
The narrative should address activities conducted over the entire project period and
must include the following items the order listed: Purpose, Background, and Need: these sections, applicants should include
information regarding the jurisdiction estimated adolescent population size, recent HPV
vaccination coverage data, and estimated HPV-associated disease burden. Descriptions prior immunization coalition activities barriers the establishment coalitions
the past should included. Applicants should describe the jurisdiction current
communications efforts (if applicable) and resources, including IIS, and outline the
resource needs required accomplish this project. Additional IIS details provided
should include: Numbers providers reporting the IIS, number and percentage adolescents
captured the IIS, number and percentage adolescents with documentation least vaccinations administered between the ages years the IIS,
CDC Supplement Non-Research
Rev. 01/2011
Descriptions any previous current activities that utilize the IIS conduct
reminder/recall and/or assessment vaccination coverage levels. Implementation Methods and Plan:
Applicants should: fully responsive feasible the activities described Part (under
 Recipient Activities Describe how the HPV vaccination joint initiative stakeholders will recruited,
convened, and retained ongoing efforts plan joint and complementary
activities increase HPV vaccination coverage and assess effectiveness
activities. Applicants are encouraged build upon pre-existing initiatives
coalitions. Describe plans track and report process measures for the HPV vaccination joint
initiative. Include public health cancer prevention and control programs developing
proposals and, the fullest extents possible, implementing plans (e.g., cancer
prevention and control programs and their partners should invited participate
actively the HPV vaccination joint initiative). Identify, partner, and plan strategies with federally qualified health centers
(FQHCs) and rural health centers (RHCs) their jurisdictions provide HPV
vaccination (and other vaccines) VFC-eligible pre-teens and adolescents
(including the underinsured and the uninsured) well uninsured young
adults, whose vaccinations could provided using 317 funds. FQHC and RHC
representatives should invited participate actively the HPV vaccination
joint initiative. Provide overview the proposed communication campaign. Note that some
elements the communication campaign may discussed and decided upon
consultation with CDC health communications experts and project officers
following awardees receipts Notices Awards. This approach should allow
awardees take most advantage the breadth CDC-prepared materials and
resources. Describe plans track and report process measures for the communication
campaign [e.g., number visits applicant website and other metrics that
reflect use web content (including digital ads), numbers flyers disseminated,
and numbers health fairs staffed]. Describe plans use IIS data identify and disseminate reminder recall notices parents adolescents aged years who are either due overdue for any
HPV vaccine dose. Proposals that include plans assess adolescents for other
recommended vaccines are encouraged, this will not impede dissemination
notices regarding HPV vaccination. Applicants who are able focus only
HPV vaccination status are encouraged include language reminder recall
CDC Supplement Non-Research
Rev. 01/2011
notices designed prompt parents/guardians discuss with providers any other
vaccines that might recommended for their teens.
Indicate whether reminder/recall will centralized provider-based.*
choosing and tailoring proposed approaches, applicants should prioritize
reminder/recall approaches that would allow reminder/recall reach the greatest
numbers adolescents feasible. For example, provider-based recall
proposed, applicants might collaborate with health care systems and /or plan
identify and recruit immunization providers who collectively serve large
proportion the jurisdiction adolescents.
Specify the following: the proposed IIS reminder/recall activity consistent with Modeling
Immunization Registry Operations Work Group (MIROW) best practices
available at: http://www.immregistries.org/resources/aira-mirow
ii) Dissemination method(s) for reminder/recall notices (e.g., mail, phone, email,
text message, combination methods),
iii) Frequency dissemination reminder/recall notices,
iv) Methods for identifying adolescents aged years included the IIS who
are due overdue for more HPV vaccine doses.
Describe plans for tracking process and outcome measures including numbers
reminder/recall notices sent, numbers returned undeliverable notices, and
numbers adolescents receiving >1, >2, and HPV vaccine doses.
Estimate the number additional immunization providers serving adolescents
who will able receive AFIX visits through this project and, applicable, the
number providers who could receive additional outreach /education
complementing their previously planned, routine AFIX visits.
Specify for assessment and feedback activities: Methods for determining vaccination coverage levels
ii) Methods for assessing missed vaccination opportunities
iii) Frequency assessments (at minimum every months)
iv) Methods and schedules for disseminating reports Methods for tracking follow-up discussions with providers
Describe plans for tracking process and outcome measures including numbers
providers receiving assessment and feedback site visits, baseline HPV vaccination
coverage estimates (for >1, >2, and HPV vaccine doses), and follow-up HPV
vaccination coverage estimates for the three measures specified above.
Describe strategies achieve the objectives related improving providers 
knowledge, skills, avoidance missed vaccination opportunities, and adherence ACIP HPV vaccination recommendations.
Describe plans for monitoring and reporting changes knowledge, attitudes
and practices among providers and office staff following their receipt
educational interventions. For example, planning could include pre- and posttesting whenever feasible.
CDC Supplement Non-Research
Rev. 01/2011 Describe plans disseminate lessons learned through presentations HPV
vaccination joint initiative stakeholders and through presentations other
appropriate venues and partner collaboration.
*NOTE: IIS reminder/recall activities will conducted the provider level,
applicants must also describe the number providers recruited, methods for
recruiting and training providers, follow-up activities with providers ensure they are
conducting activity planned, applicant plans for providing technical assistance
providers needed, and plans for collecting process measures required for monthly and
quarterly progress reports CDC. Timeline: Applicants should provide clear, realistic timeline for activities that will
result completion the plan consistent with award specifications. The timeline should
indicate initiation and completion activities sequence and parallel, appropriate.
Milestones that correlate with the applicant plan and that can used track plan
implementation should included. Capacity: Provide overview the staff members who will conducting each
proposed activity, the background and experience the personnel, and how they will
operate implement this program effectively. Budget justification (not counted the page limit): Travel described activities
including travel for partner collaboration should reflected the application budget.
Additional information may included the application appendices. The appendices
must uploaded the Other Attachments Form application package Grants.gov.
Note: appendices will not counted toward the narrative page limit. This additional
information includes:
 Curriculum vitas, resumes, lists organizations that are planned for recruitment
for the HPV vaccination initiative, and organizational charts
Additional information submitted via Grants.gov must uploaded PDF file format,
and should named:
 Applicants should label all electronic files clearly identify the specific
component the application. more than should uploaded per application.
CDC Assurances and Certifications can found the CDC Web site the following
Internet address: http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm and
required for competing continuations.
CDC Supplement Non-Research
Rev. 01/2011
Additional requirements for additional documentation with the application are listed
Section VI. Award Administration Information; subsection entitled Administrative and
National Policy Requirements. 
Submission Dates and Times
This announcement the definitive guide application content, submission, and
deadline. supersedes information provided the application instructions. the
application submission does not meet the deadline published herein, will not eligible
for review and the recipient will notified the application did not meet the submission
requirements.
Letter Intent Deadline Date: August 16, 2013, 5:00 p.m. Eastern Time
Application Deadline Date: September 2013, 5:00 p.m. Eastern Time
Explanation Deadlines: Application must successfully submitted Grants.gov
5:00 p.m. Eastern Time the deadline date.
Intergovernmental Review
The application subject Intergovernmental Review Federal Programs, governed Executive Order (EO) 12372. This order sets system for state and local
governmental review proposed federal assistance applications. Contact the state single
point contact (SPOC) early possible alert the SPOC prospective applications
and receive instructions the State process. Visit the following Web address get
the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html.
Funding Restrictions
Restrictions, which must taken into account while writing the budget, are follows:
 
Sec. 503(a) part any appropriation contained this Act transferred
pursuant section 4002 Public Law 111-148 shall used, other than for
normal and recognized executive-legislative relationships, for publicity
propaganda purposes, for the preparation, distribution, use any kit, pamphlet,
booklet, publication, electronic communication, radio, television, video
presentation designed support defeat the enactment legislation before the
Congress any State local legislature legislative body, except
presentation the Congress any State local legislature itself, designed
support defeat any proposed pending regulation, administrative action,
order issued the executive branch any State local government itself.
(b) part any appropriate contained this Act transferred pursuant
section 4002 Public Law 111-148 shall used pay the salary expenses
any grant contract recipient, agent acting for such recipient, related any
CDC Supplement Non-Research
Rev. 01/2011
activity designed influence the enactment legislation, appropriations,
regulation, administrative action, Executive Order proposed pending before
the Congress any State government, State legislature local legislative body,
other than normal and recognized executive-legislative relationships
participation agency officer State, local tribal government
policymaking and administrative processes within the executive branch that
government.
(c) The prohibitions subsections (a) and (b) shall include any activity
advocate promote any proposed, pending, future Federal, State, local tax
increase, any proposed, pending, future requirement restriction any
legal consumer product, including its sale marketing, including but not limited the advocacy promotion gun control.
 
Sec. 218. None the funds made available this title may used, whole part, advocate promote gun control.
 
Sec 253. Notwithstanding any other provision this Act, funds appropriated this Act shall used carry out any program distributing sterile needles
syringes for the hypodermic injection any illegal drug.
 
Sec 738. None the funds made available this Act may used enter into contract, memorandum understanding, cooperative agreement with, make grant to, provide loan loan guarantee any corporation that was
convicted (or had officer agent such corporation acting behalf the
corporation convicted) felony criminal violation under any Federal State
law within the preceding months, where the awarding agency aware the
conviction, unless the agency has considered suspension debarment the
corporation, such officer agent, and made determination that this further
action not necessary protect the interests the Government.
 
Sec 739. None the funds made available this act may used enter into
contract, memorandum understanding, cooperative agreement with, make
grant to, provide loan loan guarantee to, any corporation that any unpaid
Federal tax liability that has been assessed, for which all judicial and
administrative remedies have been exhausted have lapsed, and that not being
paid timely manner pursuant agreement with the authority responsible
for collecting the tax liability, where the awarding agency aware the unpaid
tax liability, unless the agency has considered suspension debarment the
corporation and made determination that this further action not necessary
protect the interests the Government.
 
Sec 433. None the funds made available this Act may used enter into contract, memorandum understanding, cooperative agreement with, made
CDC Supplement Non-Research
Rev. 01/2011 grant to, provide loan loan guarantee to, any corporation that was
convicted (or had officer agent such corporation acting behalf the
corporation convicted) felony criminal violation under any Federal law
within the preceding months, where the awarding agency aware the
conviction, unless the agency has considered suspension debarment the
corporation, such officer agent and made determination that this further
action not necessary protect the interests the Government.
 
Sec 434. None the funds made available this act may used enter into
contract, memorandum understanding, cooperative agreement with, make
grant to, provide loan loan guarantee to, any corporation with respect
which any unpaid Federal tax liability that has been assessed, for which all
judicial and administrative remedies have been exhausted have lapsed, and that not being paid timely manner pursuant agreement with the authority
responsibly for collecting the tax liability, unless the agency has considered
suspension debarment the corporation and made determination that this
further action not necessary protect the interests the Government.
 
Recipients may not use funds for research.
 
Recipients may not use funds for clinical care.
 
Recipients may only expend funds for reasonable program purposes, including
personnel, travel, supplies, and services, such contractual.
 
Awardees may not generally use HHS/CDC/ATSDR funding for the purchase
furniture equipment. Any such proposed spending must identified the
budget.
 
The direct and primary recipient cooperative agreement program must
perform substantial role carrying out project objectives and not merely serve conduit for award another party provider who ineligible.
The recipient can obtain guidance for completing detailed justified budget the CDC website, the following Internet address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm.
Other Submission Requirements
Application Submission
Submit the application electronically using the forms and instructions posted for this
funding opportunity www.Grants.gov. access the Internet not available
the recipient encounters difficulty accessing the forms on-line, contact the HHS/CDC
CDC Supplement Non-Research
Rev. 01/2011
Procurement and Grant Office Technical Information Management Section (PGO TIMS)
staff (770) 488-2700 for further instruction.
Note: Application submission not concluded until successful completion the
validation process. After submission your application package, recipients will receive submission receipt email generated Grants.gov. Grants.gov will then generate
second e-mail message recipients which will either validate reject their submitted
application package. This validation process may take long two (2) business days.
Recipients are strongly encouraged check the status their application ensure
submission their application package complete and submission errors exists. guarantee that you comply with the application deadline published the Funding
Opportunity Announcement, recipients are also strongly encouraged allocate
additional days prior the published deadline file their application. Non-validated
applications will not accepted after the published application deadline date. the event that you not receive validation email within two (2) business days application submission, please contact Grants.gov. Refer the email message
generated the time application submission for instructions how track your
application the Application User Guide, Version 3.0 page 57.
Electronic Submission Application:
Applications must submitted electronically www.Grants.gov. Electronic
applications will considered having met the deadline the application has been
successfully made available CDC for processing from Grants.gov the deadline date.
The application package can downloaded from www.Grants.gov. Recipients can
complete the application package off-line, and then upload and submit the application via
the Grants.gov website. The recipient must submit all application attachments using
PDF file format when submitting via Grants.gov. Directions for creating PDF files can found the Grants.gov website. Use file formats other than PDF may result the
file being unreadable staff.
Applications submitted through Grants.gov (http://www.grants.gov), are electronically
time/date stamped and assigned tracking number. The AOR will receive e-mail
notice receipt when HHS/CDC receives the application. The tracking number serves
document submission and initiate the electronic validation process before the application made available CDC for processing. the recipient encounters technical difficulties with Grants.gov, the recipient should
contact Grants.gov Customer Service. The Grants.gov Contact Center available
hours day, days week. The Contact Center provides customer service the
recipient community. The extended hours will provide recipients support around the
clock, ensuring the best possible customer service received any time needed. You
CDC Supplement Non-Research
Rev. 01/2011
can reach the Grants.gov Support Center 1-800-518-4726 email
support@grants.gov. Submissions sent e-mail, fax, thumb drives
applications will not accepted.
Organizations that encounter technical difficulties using www.Grants.gov submit
their application must attempt overcome those difficulties contacting the
Grants.gov Support Center (1-800-518-4726, support@grants.gov). After consulting
with the Grants.gov Support Center, the technical difficulties remain unresolved and
electronic submission not possible meet the established deadline, organizations
may submit request prior the application deadline email the Grants
Management Specialist/Officer for permission submit paper application.
organizations request for permission must: (a) include the Grants.gov case number
assigned the inquiry, (b) describe the difficulties that prevent electronic submission
and the efforts taken with the Grants.gov Support Center (c) submitted the Grants
Management Specialist/Officer least calendar days prior the application
deadline. Paper applications submitted without prior approval will not considered. paper application authorized, the recipient will receive instructions from PGO
TIMS submit the original and two hard copies the application mail express
delivery service. Application Review Information
Eligible recipients are required provide measures effectiveness that will demonstrate
the accomplishment the various identified objectives the FOA IP13-1301.
Measures effectiveness must relate the performance goals stated the Purpose 
section this announcement. Measures effectiveness must objective, quantitative
and measure the intended outcome the proposed program. The measures
effectiveness must included the application and will element the evaluation the submitted application.
Criteria
Eligible recipients will evaluated against the following criteria: Purpose, Background, and Need (25 Points): what extent does the applicant
justify the need for this project within the applicant jurisdiction? Parameters that might considered include comparatively larger estimated adolescent population size, lower
HPV vaccination coverage, evidence decreasing stagnating coverage, and higher
HPV-related disease burden. For example, were 2011 NIS-TEEN coverage rates among
females aged years for HPV vaccine doses less than the national averages 53% and 35%, respectively? Have HPV-associated cervical cancer rates been
estimated per 100,000 females? Are other disease burden data cited the awardee
CDC Supplement Non-Research
Rev. 01/2011 provide evidence this awardee need? Does the narrative describe current
previous efforts promote HPV vaccination through coalition development,
communications directed the public, outreach immunization providers? does
the narrative describe past barriers such work that might transcended through this
award? Has the applicant described the IIS? Has the applicant described the resources
that currently exist and outlined the resource needs required accomplish this project? Implementation Plan and Methods (50): the plan adequate address fully each the required elements listed the purpose this announcement? the plan complete,
sound, and practical? Does the plan include proposed quantitative process and outcome
measures? Are the proposed methods feasible? what extent will they accomplish the
program goal increasing HPV vaccination coverage among adolescents? Timeline (10 Points): Does the plan include well-defined, reasonable, realistic
timeline that will result completion the plan within award specifications? Are there
milestones that correlate with the applicant plan and that can used track plan
implementation? Capacity (15 Points): Does the implementation plan identify adequate staff way
that demonstrates applicant understanding the labor resources needed implement
each the specified activities consistent with the defined purpose? personnel include public information officers directors communication? Does
the plan demonstrate the applicant engagement the jurisdiction public health cancer
prevention and control program planning and implementation? Does the plan entail
collaboration with the jurisdiction FQHCs and RHCs? For any these staff public
health entities that are not included, does the plan detail justifiable reasons why they are
not? proposed staffing resources have prior experience their proposed implementation
role(s)? Are staff roles clearly defined? described, will staff sufficient
accomplish the identified program goals? what extent does applicant propose using
existing staff versus new and/or existing contracts hiring new staff accomplish
stated objectives? Does the implementation plan demonstrate the capacity spend
requested funds within the performance period?
Budget (SF 424A) and Budget Narrative (Reviewed, but not scored)] Although the
budget not scored recipients should consider the following development their
budget: the itemized budget for conducting the project and justification reasonable and
consistent with stated objectives and planned program activities? Travel reverse site
visit Atlanta GA, partner collaboration, and other necessary meetings should
CDC Supplement Non-Research
Rev. 01/2011
included the application budget. addition, proposed budgets should allocate 
25% funds implement the communication campaign. the recipients requests indirect costs the budget, copy the indirect cost rate
agreement required. the indirect cost rate provisional rate, the agreement should less than months age. The indirect cost rate agreement should uploaded
PDF file with Other Attachment Forms when submitting via Grants.gov.
Review and Selection Process
Review
Eligible applications will jointly reviewed for responsiveness NCIRD and PGO.
Incomplete applications and applications that are non-responsive will not advance
through the review process. Recipients will notified writing the results. objective review panel will evaluate complete and responsive applications according the criteria listed Section Application Review Information, subsection entitled
 Criteria. The objective review panel will review and rank each application based
the evaluation criteria provided this FOA. The review panel will consist CDC
employees the majority whom will from outside the funding center (NCIRD) 
and accordance with CDC objective review policies and procedures. CDC will develop list recommended awardees rank order based the results the objective review
panel.
Selection
Applications will funded order score and rank determined the review panel. addition, the following factors may affect the funding decision: Comparatively larger
estimated unvaccinated female adolescent population size, lower HPV vaccination
coverage, evidence decreasing stagnating HPV vaccination coverage, and higher
HPV-related disease burden. CDC will provide justification for any decision fund out rank order.
VI. Award Administration Information
Award Notices
Successful recipients will receive Notice Award (NoA) from the CDC Procurement
and Grants Office. The NoA shall the only binding, authorizing document between
the recipient and CDC. The NoA will signed authorized Grants Management
Officer and e-mailed the program director.
Unsuccessful recipients will receive notification the results the application review.
CDC Supplement Non-Research
Rev. 01/2011
Administrative and National Policy Requirements
Successful recipients must comply with the administrative requirements outlined
Code Federal Regulations (CFR) Part Part 92, appropriate. For competing
supplements, ARs remain effect published the original announcement.
 
 
 
 
 
 
 
 
 
 
AR-7
AR-8
AR-10
AR-11
AR-12
AR-14
AR-20
AR-24
AR-25
AR-26
 
 
AR-27
AR-29
 
AR-30
Executive Order 12372
Public Health System Reporting Requirements
Smoke-Free Workplace Requirements
Healthy People 2020
Lobbying Restrictions
Accounting System Requirements
Conference Support
Health Insurance Portability and Accountability Act Requirements
Release and Sharing Data
National Historic Preservation Act 1966
(Public Law 89-665, Stat. 915)
Conference Disclaimer and Use Logos
Compliance with E.O. 13513 Federal Leadership Reducing
Text Messaging While Driving, October 2009.
Information Letter 10-006. Compliance with Section 508 the
Rehabilitation Act 1973
Additional information the requirements can found the CDC Web site the following
Internet address: http://www.cdc.gov/od/pgo/funding/Addtl_Reqmnts.htm.
For more information the Code Federal Regulations, see the National Archives and
Records Administration the following Internet address:
http://www.access.gpo.gov/nara/cfr/cfr-table-search.html
Reporting
Federal Funding Accountability And Transparency Act 2006 (FFATA): Public Law
109-282, the Federal Funding Accountability and Transparency Act 2006 amended
(FFATA), requires full disclosure all entities and organizations receiving Federal funds
including grants, contracts, loans and other assistance and payments through single
publicly accessible Web site, USASpending.gov. The Web site includes information
each Federal financial assistance award and contract over $25,000, including such
information as: The name the entity receiving the award The amount the award Information the award including transaction type, funding agency, etc.
CDC Supplement Non-Research
Rev. 01/2011 The location the entity receiving the award unique identifier the entity receiving the award; and Names and compensation highly-compensated officers (as applicable)
Compliance with this law primarily the responsibility the Federal agency. However,
two elements the law require information collected and reported recipients: information executive compensation when not already reported through the Central
Contractor Registry; and similar information all sub-awards/subcontracts/
consortiums over $25,000.
For the full text the requirements under the Federal Funding Accountability and
Transparency Act 2006, please review the following website:
http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=109_cong_billsdocid=f:s2590enr.txt.pdf.
Section 220 Prevention Fund Reporting Requirements
Responsibilities for Informing Sub-recipients:
 
 
Recipients agree separately identify each sub-recipient and document the
time sub-award and the time disbursement funds, the Federal award
number, any special CFDA number assigned for 2012 PPHF fund purposes, and
amount PPHF funds.
Recipients agree separately identify each sub-recipient, and document the
time sub-award and the time disbursement funds, the Federal award
number, CFDA number, and amount 2012 PPHF funds. When recipient
awards 2012 PPHF funds for existing program, the information furnished
sub-recipients shall distinguish the sub-awards incremental 2012 PPHF funds
from regular sub-awards under the existing program.
Reporting Requirements under Section 203 the 2012 Enacted Appropriations Bill for
the Prevention and Public Health Fund, Public Law 111-5:
This award requires the recipient complete projects activities which are funded
under the 2012 Prevention and Public Health Fund (PPHF) and report use PPHF
funds provided through this award. Information from these reports will made available the public.
Recipients awarded grant, cooperative agreement, contract from such funds with
value $25,000 more shall produce reports semi-annual basis with reporting
cycle January June and July December 31, and email such reports (in 508
compliant agreement later than calendar days after the end each reporting period
(i.e., July and January 20, respectively). Recipient reports shall reference the notice
award number and title the grant cooperative agreement, and include summary
CDC Supplement Non-Research
Rev. 01/2011
the activities undertaken and identify any sub-grants sub-contracts awarded (including
the purpose the award and the identity the [sub] recipient).
Each funded recipient must provide CDC with the following reports: Quarterly progress report, due 120 days after award and then quarterly thereafter. Federal Financial Report (SF-425) and annual progress report, more than
days after the end the budget period. Final Performance and Federal Financial Report, more than days after the
end the project period.
These reports must submitted the attention the Grants Management Specialist
listed the Section VII below entitled Agency Contacts. 
VII. Agency Contacts
CDC encourages inquiries concerning this announcement.
For programmatic technical assistance and general inquiries, contact:
Christine Robinette Curtis, MD, MPH, FAAP, Project Officer
Department Health and Human Services
Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases
Telephone: 404-639-8389
E-mail: rcurtis@cdc.gov
For financial, grants management, budget assistance and general inquiries, contact:
Michael Vance, Grants Management Specialist
Department Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, K-14
Atlanta, 30341
Telephone: 770-488-2686
E-mail: mvance@cdc.gov
For application submission questions, contact:
Technical Information Management Section
Department Health and Human Services
CDC Procurement and Grants Office
2920 Brandywine Road, E-14
CDC Supplement Non-Research
Rev. 01/2011
Atlanta, 30341
Telephone: 770-488-2700
Email: pgotim@cdc.gov
CDC Telecommunications for the hearing impaired disabled available at: TTY 1888-232-6348
VIII. Other Information
Selected references:
CDC. National and state vaccination coverage among adolescents aged years 
United States, 2011. MMWR 2012;61:671
CDC. Quadrivalent human papillomavirus vaccine: Recommendations the Advisory
Committee Immunization Practices. MMWR 2007; (No. RR-2):1 24.
Satterwhite CL, Torrone Meites al. Sexually transmitted infections among
women and men: prevalence and incidence estimates, 2008. STD 2013:40(3):187 93.
Chesson HW, Ekwueme DU, Saraiya Watson Lowy DR, Markowitz LE.
Estimates the annual direct medical costs the prevention and treatment disease
associated with human papillomavirus the United States. Vaccine 2012; 30:6016 19.
Jemal Simard EP, Dorell al. Annual report the nation the status cancer,
1975 2009, featuring the burden and trends human papillomavirus (HPV) associated
cancers and HPV vaccination coverage levels. Natl Cancer Inst 2013 Feb
105(3):175 201.
CDC. Human papillomavirus-associated cancers United States, 2004 2008. MMWR
2012; 61:258 61.
Lacey CJN, Lowndes CM, Shah KV. Chapter Burden and management noncancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 Aug 31; Suppl
3:S3/35 41.
CDC. Recommendations the use quadrivalent human papillomavirus vaccine
males Advisory Committee Immunization Practices (ACIP), 2011. MMWR 2011;
60:1705
CDC Supplement Non-Research
Rev. 01/2011
CDC. Advisory Committee Immunization Practices (ACIP) recommended
immunization schedules for persons aged through years and adults aged years
and older United States, 2013. MMWR 2013; (Suppl 1):1 19. Department Health and Human Services. Healthy people 2020. Washington, DC: Department Health and Human Services; 2012. Available
http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=23 Page last updated September 13, 2012; accessed September 20, 2012.
CDC. HPV-associated cervical cancer rates state. Available at:
http://www.cdc.gov/cancer/hpv/statistics/state/cervical.htm. Page last updated April 18,
2012. Accessed June 13, 2012.
CDC. Recommendations the use quadrivalent human papillomavirus vaccine
males Advisory Committee Immunization Practices (ACIP), 2011. MMWR 2011;
60:1705
Dorell Human papillomavirus (HPV) vaccination coverage the United States:
National Immunization Survey Teen, 2006 2011. Advisory Committee for
Immunization Practices. October 25, 2012; available at:
http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-oct-2012/02-HPVDorell.pdf Accessed June 28, 2013.
Kennedy Stokley Curtis CR, Gust Limited awareness vaccines recommended
for adolescents and other results from two national consumer surveys the United
States. Adolesc Health. 2012 Feb; 50(2):198 200.
CDC. Guide Community Preventive Services. Available at:
http://www.thecommunityguide.org/vaccines/universally/index.html. Page last updated
January 2011. Accessed October 12, 2012.
Kempe Saville Dickinson LM, al. Population-based versus practice-based recall
for childhood immunizations: randomized controlled comparative effectiveness trial.
AJPH 2013; 103(6):1116 23.
Khan Curtis CR, Ekwueme DU, Stokley Walker Roland Benard Saraiya Preventing cervical cancer: Overviews the National Breast and Cervical Cancer
Early Detection Program and immunization programs. Cancer 2008; 113(10
Suppl):3004 12.
CDC. National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
Available at: http://www.cdc.gov/cancer/nbccedp/ Page last updated: July 2013.
Accessed July 2013.
CDC Supplement Non-Research
Rev. 01/2011
CDC. National Comprehensive Cancer Control Program (NCCCP). Available at:
http://www.cdc.gov/cancer/ncccp/about.htm Page last updated: July 2013. Accessed
July 2013.
American Immunization Registry Association (AIRA). Reminder/recall immunization
information systems: Recommendations the AIRA and Modeling Immunization
Registry Operations Work Group (MIROW). Released April 10, 2009.
Available at: http://www.immregistries.org/resources/AIRA-MIROW_RR_041009.pdf
Accessed July 2013.
Other CDC funding opportunity announcements can found www.grants.gov.
CDC Supplement Non-Research
Rev. 01/2011